Testimony Before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding insulin icodec May 24, 2024
Report: Thirty-One Years of Pharmaceutical Industry Criminal and Civil Penalties: 1991-2021 May 21, 2024
Letter to the CDC and FDA Regarding Recent Health Advisory on Clusters of Patients with Adverse Events From Certain Botulinum Toxin Injections April 30, 2024
Comment regarding the FDA’s proposed funding of the RADARS drug abuse surveillance system December 18, 2023
Petition to the FDA to Strengthen Safety Warning for Botox and Related Drugs and Remove Misleading Claims From Botox/Botox Cosmetic Labeling December 12, 2023
Comments Regarding the Food and Drug Administration’s Notice of Proposed Rule on Medication Guides: Patient Medication Information (FDA-2019-N-5959) November 27, 2023
Testimony Before the FDA’s Meeting of the Pulmonary-Allergy Drugs Advisory Committee Regarding Gefapixant November 17, 2023